

**Limited Review Report on the Statement of unaudited Standalone financial results of TAKE Solutions Limited for the quarter ended June 30, 2024 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To the Board of Directors of **TAKE Solutions Limited**

**Introduction**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **TAKE Solutions Limited** ("the Company") for the quarter ended 30<sup>th</sup> June 2024 (the "Statement") together with notes thereon, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulation, 2015"), which we have initialed for identification purposes only.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 22<sup>nd</sup> January 2025 and has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulation, 2015"). Our responsibility is to issue a report on the Statement based on our review.

**Scope of Review**

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of



making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Basis for Qualified Conclusion**

4. As stated in Note No. 3 to the statement, tax assets appearing in the standalone financial statements of the Company to an extent of INR 88.32 Million pertain to various assessment years relating to the financial periods ending upto March 31, 2021. In the absence of sufficient appropriate evidence to corroborate management's assessment of recoverability of these balances we are unable to comment on the carrying value of above receivables and the shortfall, if any, on the amount that would be ultimately realizable from the tax authorities considering the fact that the Company's contingent liabilities as at June 30, 2024 include contingent liabilities aggregating to INR 113.30 Million pertaining to direct tax litigations pending before various forums relating to the above periods, for which the assessment on whether the outflow of resource embodying economic benefits is probable or not as per the requirements of Ind AS 37- "Provisions, Contingent Liabilities and Contingent Assets" is in progress. In the absence of sufficient evidence, we are unable to comment upon the appropriateness and classification of the aforesaid amounts as provision or contingent liabilities as at June 30, 2024 in accordance with Ind AS 37, "Provisions, Contingent Liabilities and Contingent Assets" and the consequential impact, if any, on the total liabilities and loss as at and for the period then ended.
5. Considering the business operations of the Company are severely impacted as stated in Note No. 2 to the Statement, we are unable to comment on the usage/recoverability of indirect tax credit/receivables of INR 52.90 Million and the consequential impact, if any, on the total assets and loss as at and for the period then ended is not ascertainable.
6. As stated in Note No. 2 to the Statement, the Company has incurred huge loss after tax of INR 2072.51 Million for the year ended March 31, 2024 on account of recognition of impairment loss on certain financial assets resulting in substantial reduction of networth of the Company as on March 31, 2024. Further, significant deterioration in the value of the assets used to generate cash flows was seen over the last two years as evidenced by lower volume of business. In addition, the Company has significant litigations under direct tax law and the outcome & impact of which is



unascertainable. Furthermore, the Company has significant unpaid statutory dues. The cumulative effect of these factors and the possible impact of the matters stated in paragraphs (4) & (5) above indicate the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern and therefore the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite the above factors, the Standalone Financial Results have been prepared on a "going concern basis" and no adjustment has been made to the carrying value of assets and liabilities, as the Company subsequent to the reporting period has successfully divested its 100% stake held in subsidiary Ecron Acunova Limited, the proceeds of which would alleviate immediate liquidity requirements to meet pending statutory and debt obligations of subsidiary through this Financial Year. Further, the Company has pragmatically initiated conversations for diversification of operations to other verticals as subject to current non-compete obligations applicable in the CRO industry. The company's strategy is to solicit mutually rewarding business partnerships/Mergers & Acquisitions in non-cash transactions and a positive closure of the deal is expected in the Financial Year 2026. While the plans for diversification of operations to other verticals are under discussion, the consequential impact on the going concern assumption is not ascertainable at this stage and hence we are unable to comment on whether the preparation of standalone financial results on a going concern basis is appropriate and on the consequential impact, if any, on the standalone financial results.

#### Emphasis of Matter

7. We draw attention to Note No 8 regarding non-compliance of provisions of LODR in respect of appointment of Compliance officer (Qualified Company Secretary).

Our conclusion is not modified in respect of the above matter.



### **Qualified Conclusion**

8. Based on our review conducted as stated above, ***except for the effects/possible effects of the matters stated under Basis for Qualified Conclusion Section above***, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Sundar Srinivasan & Sridhar  
Chartered Accountants**

Firm Registration No: 004201S



**V Vijay Krishna**

**Partner**

Membership No: 216910

UDIN: 25216910BMMLPQ8679

Place: Chennai

Date: January 22, 2025




**TAKE SOLUTIONS LTD**

CIN: L63090TN2000PLC046338

Regd. Office : 56, Ragas Building, Dr. Radhakrishnan Salai, Mylapore, Chennai 600 004  
www.takesolutions.com

**Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2024**

(₹ In Million except per share data)

Sl. No.	Particulars	Quarter Ended		Year Ended	
		Jun 30, 2024	Mar 31, 2024	Jun 30, 2023	Mar 31, 2024
		(Unaudited)	(Audited) - Refer Note No 9	(Unaudited)	(Audited)
A	<b>Continuing Operations</b>				
1	<b>Income</b>				
	Revenue from operations	8.99	-	54.21	54.21
	Other Income	(4.54)	(125.03)	0.11	(116.69)
	<b>Total Income</b>	<b>4.45</b>	<b>(125.03)</b>	<b>54.32</b>	<b>(62.48)</b>
2	<b>Expenses</b>				
	Cost of revenue	-	-	31.50	31.50
	Employee benefit expenses	3.08	4.28	6.26	20.11
	Finance cost	1.62	1.66	2.05	7.33
	Depreciation and amortisation	0.13	0.12	2.99	7.16
	Other expenses	2.99	75.09	6.39	97.84
	<b>Total Expenses</b>	<b>7.82</b>	<b>81.15</b>	<b>49.19</b>	<b>163.94</b>
3	<b>Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>(3.37)</b>	<b>(206.18)</b>	<b>5.13</b>	<b>(226.42)</b>
4	<b>Exceptional items</b>				
	Loss on impairment	-	(480.45)	(3.62)	(484.07)
	<b>Profit/(Loss) before tax (3+4)</b>	<b>(3.37)</b>	<b>(686.63)</b>	<b>1.51</b>	<b>(710.49)</b>
5	<b>Tax expense / (Reversal)</b>				
	Current tax	0.57	-	1.59	-
	Deferred tax	-	5.98	0.22	5.70
	Shortfall / (excess) provision of earlier years	-	-	-	34.38
6	<b>Profit/(Loss) for the period from continuing operations (4-5)</b>	<b>(3.94)</b>	<b>(692.61)</b>	<b>(0.30)</b>	<b>(750.57)</b>
B	<b>Discontinued Operations</b>				
7	Profit/(Loss) from discontinued operations before tax	(474.89)	(1,322.27)	0.11	(1,321.94)
8	Less : Tax expense on discontinued operations	-	-	-	-
	<b>Profit/(Loss) for the period from discontinued operations after tax</b>				
9	<b>(7-8)</b>	<b>(474.89)</b>	<b>(1,322.27)</b>	<b>0.11</b>	<b>(1,321.94)</b>
10	<b>Profit/(Loss) for the period</b>	<b>(478.83)</b>	<b>(2,014.88)</b>	<b>(0.19)</b>	<b>(2,072.51)</b>
11	<b>Other Comprehensive Income</b>				
	a) i) Items that will not be reclassified to profit or loss	(0.05)	0.24	(1.58)	(1.44)
	ii) Income tax on items that will not be reclassified to profit or loss	-	(0.06)	0.40	0.36
	b) i) Items that will be reclassified to profit or loss	-	-	-	-
	ii) Income tax on items that will be reclassified to profit or loss	-	-	-	-
	<b>Total Other Comprehensive Income</b>	<b>(0.05)</b>	<b>0.18</b>	<b>(1.18)</b>	<b>(1.08)</b>
12	<b>Total Comprehensive Income (10+11)</b>	<b>(478.88)</b>	<b>(2,014.70)</b>	<b>(1.37)</b>	<b>(2,073.59)</b>
13	<b>Paid-up equity share capital (Face value ₹ 1/- each)</b>	<b>147.93</b>	<b>147.93</b>	<b>147.93</b>	<b>147.93</b>
14	<b>Earnings per share (of ₹ 1/- each) (not annualised)</b>				
	(a) Basic				
	(i) Continuing operations	(0.03)	(4.68)	(0.00)	(5.07)
	(ii) Discontinued operations	(3.21)	(8.94)	0.00	(8.94)
	<b>Total Operations</b>	<b>(3.24)</b>	<b>(13.62)</b>	<b>(0.00)</b>	<b>(14.01)</b>
	(b) Diluted				
	(i) Continuing operations	(0.03)	(4.68)	(0.00)	(5.07)
	(ii) Discontinued operations	(3.21)	(8.94)	0.00	(8.94)
	<b>Total Operations</b>	<b>(3.24)</b>	<b>(13.62)</b>	<b>(0.00)</b>	<b>(14.01)</b>

**Explanatory notes to the unaudited statement of standalone financial results for the quarter ended June 30, 2024**

- 1 The Standalone Financial Results have been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 (the "Act") read with relevant Rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). The Standalone Financial Results for the quarter ended June 30, 2024 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the company in their respective meetings held on January 22, 2025. The statutory auditors of the Company have carried out limited review of the the standalone financial results for the quarter ended June 30, 2024 and have issued a modified conclusion.
- 2 The Company has incurred huge loss after tax of INR 2,072.51 Million for the year ended March 31, 2024 on account of recognition of impairment loss on certain financial assets resulting in substantial reduction in networth of the Company as on March 31, 2024 and there has been significant reduction in the volume of business. Furthermore, the Company has significant unpaid statutory dues. The cumulative effect of these factors may indicate the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern. However, the Standalone Financial Results have been prepared on a "going concern basis" and no adjustment has been made to the carrying value of assets and liabilities, as the Company, subsequent to the reporting period ended has successfully divested its subsidiary Ecron Acunova Limited, the proceeds of which would alleviate immediate liquidity requirements to meet pending statutory and debt obligations through this Financial Year. Further, the Company has pragmatically initiated conversations for diversification of operations to other verticals as subject to current non-compete obligations applicable in the CRO industry. The company's strategy is to solicit mutually rewarding business partnerships/Mergers & Acquisitions in non-cash transactions and a positive closure of the deal is expected in the Financial Year 2026.
- 3 According to the management, Tax Assets to an extent of ₹ 88.32 Million recognised in the standalone financial statements pertain to various assessment years relating to the financial periods ending upto March 31, 2021, are fully recoverable upon completion of the assessment / disposal of the appeals pending in various forums. The refunds are withheld/under process on account of disputes pending before various forums and no impairment is considered necessary and further the Management expects a favourable outcome on the pending tax litigations.
- 4 Exceptional items include impairment loss recognised on investments (quarter ended June 30, 2024 ₹ Nil/-, quarter ended March 31, 2024 ₹ 93.07/- Million, quarter ended June 30, 2023 ₹ 3.62/- Million & year ended March 31, 2024 ₹ 96.69 Million). Exceptional items for the quarter ended further includes impairment loss recognised on certain other financial assets (quarter ended June 30, 2024 ₹ Nil/-, quarter ended March 31, 2024 ₹ 387.38/- Million, quarter ended June 30, 2023 ₹ Nil/- & year ended March 31, 2024 ₹ 387.38/- Million).
- 5 (a) Other Income for the quarter includes share of loss from Navitas LLP of ₹ 4.54 Million (₹ 125.34/- Million for quarter ending March 31, 2024 , ₹ Nil/- for the quarter ending June 30, 2023 and ₹ 125.34/- Million for the year ended March 31, 2024). Other Income further includes gain arising out of termination of lease and write back of certain associated liabilities (quarter ended June 30, 2024 ₹ Nil/-, quarter ended March 31, 2024 ₹ Nil/-, quarter ended June 30, 2023 ₹ Nil/- & year ended March 31, 2024 ₹ 6.28/- Million)
- (b) Other Expenses include recognition of ECL on financial guarantee contracts provided for the loan taken by the subsidiary (quarter ended June 30, 2024 ₹ Nil/-, quarter ended March 31, 2024 ₹ 71.57/- Million, quarter ended June 30, 2023 ₹ Nil/- & year ended March 31, 2024 ₹ 71.57/- Million).
- 6 During the reporting period, in light of the urgency to meet these liabilities, the Board has set up a committee of the Independent Directors to aggressively pursue the sale of relevant assets of the Company and the committee of independent directors has recommended disinvestment of the entire stake held in Ecron Acunova Limited (EAL) and subsequently an active programme to locate a buyer and complete the plan was initiated. The Board in its meeting held on 13th September 2024 has approved the sale of 100% stake held in EAL for an approximate value of USD 6.50 million (on a debt-free and cash-free balance sheet and subject to appropriate level of working capital) subject to shareholders approval. In the EGM held on October 9, 2024, the shareholders have passed a special resolution approving the proposal of disinvestment of 100% stake held in EAL and the sale transaction has been successfully completed in Q3 of FY 2025. In accordance with Ind AS 105, the Company has disclosed in the statement of profit and loss the post-tax loss recognised on the measurement to fair value less costs to sell upon the disposal of the assets under the head discontinued operation.
- 7 Since the Company operates in a single segment viz Life Sciences and Support Services, disclosures under Ind AS 108. 'Segment Reporting' are not required.
- 8 Pursuant to Section 203 of the Companies Act, 2013, the company is required to have a whole time Company Secretary and further as per Regulation 6(1A) of SEBI LODR, any vacancy in the office of the Compliance Officer shall be filled by the listed entity at the earliest and in any case not later than three months from the date of such vacancy . No Company Secretary has been appointed as on date for the vacancy created on March 31, 2024 by the resignation of the erstwhile Company Secretary and the Company is confident of appointing a compliance officer at the earliest.
- 9 The figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the limited reviewed year to date figures up to the quarters ended December 31, 2023.
- 10 The Standalone Financial Results for the quarter ended June 30, 2024 are available on the Company's website ([www.takesolutions.com](http://www.takesolutions.com)) and the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com))
- 11 Figures for earlier periods have been regrouped, wherever necessary.



Place : Chennai  
Date : January 22, 2025

**For and on behalf of the Board of Directors**  
**HARIKESANALLUR**  
**RAMANI SRINIVASAN**  
Digitally signed by HARIKESANALLUR  
RAMANI SRINIVASAN  
Date: 2025.01.22 14:21:02 +05'30'  
**Srinivasan H.R.**  
**Chairman for the meeting dated January 22, 2025**